Skip to main content
. 2019 Sep 30;3(19):2804–2811. doi: 10.1182/bloodadvances.2019000458

Table 1.

Summary of baseline characteristics for all patients based on treatment approach for early-stage FL

WW, n = 85 RT, n = 171 Systemic therapy,* n = 60 Systemic + maintenance rituximab, n = 49
n/N % n/N % n/N % n/N %
Age >60 y 59/85 69.4 101/170 59.4 27/60 45.0 29/48 60.4
Male sex 49/85 57.6 96/170 56.4 33/60 55.0 31/49 63.3
ECOG PS ≥2 4/84 4.7 8/171 4.7 3/60 5.0 3/49 6.1
B symptoms present 4/85 4.7 7/167 4.2 4/60 6.7 9/49 18.4
LoNoDiam >7 cm 6/56 10.7 9/132 6.8 6/41 14.6 15/42 35.7
No. of nodal sites
 0 11/83 13.2 23/170 13.5 4/60 6.6 2/47 4.3
 1 42/83 50.6 111/170 65.3 31/60 51.6 16/47 34.0
 2 26/83 31.3 32/170 18.9 21/60 35.0 22/47 46.8
 3 4/83 4.9 4/170 2.3 2/60 3.3 5/47 10.6
 4 0/83 0 0/170 0 2/60 3.3 2/47 4.3
Extranodal present 19/85 22.3 29/171 17.0 7/60 11.7 8/47 17.0
Stage II 36/85 42.3 46/171 26.9 29/60 48.3 33/49 67.3
Grade 3A 11/82 13.4 26/165 15.8 13/59 22.0 6/45 13.3
B2M >ULN 9/49 18.3 19/68 27.9 7/41 17.1 7/28 25.0
Hb <12 g/dL 5/84 5.9 11/169 6.5 4/59 6.8 9/49 18.4
LDH >ULN 13/77 16.8 24/162 14.8 8/58 13.8 13/49 26.5
FLIPI score
 Low (0-1) 66/77 85.8 137/161 85.1 51/58 87.9 34/46 73.9
 Intermediate (2) 10/77 12.9 24/161 14.9 6/58 10.4 10/46 21.7
 High (≥3) 1/77 1.3 0/161 0 1/58 1.7 2/46 4.4

B2M, β2 microglobulin; ECOG PS, Eastern Cooperative Oncology Group performance status; Hb, hemoglobin; LDH, lactate dehydrogenase; LoNoDiam, largest nodal diameter; ULN, upper limit of normal.

*

Systemic therapy includes immunochemotherapy and CMT.